Abstract
α1-Adrenoceptor antagonists, have been documented to induce apoptosis and reduce prostate tumor vascularity in benign and malignant prostate cells. The quinazoline based α1-antagonists, doxazosin and terazosin but not tamsulosin (a sulphonamide derivative) suppress prostate growth without affecting cell proliferation. These quinazoline-mediated apoptotic effects occur via an α1-adrenoceptor independent mechanism potentially involving activation of the TGF-β signal transduction pathway. This review discusses the current knowledge of the action of quinazoline-derived α1-adrenoceptor antagonists in the benign and malignant prostate and their potential therapeutic use in the treatment of benign prostatic hyperplasia (BPH) and prostate cancer. Finally, a molecular pathway is proposed for their observed apoptotic function against prostate cells. Increased understanding of the action of these established and clinically accepted agents would provide a basis for the design of safe, effective therapeutic regimens in the treatment of prostatic diseases.
Original language | English |
---|---|
Pages (from-to) | 88-95 |
Number of pages | 8 |
Journal | Prostate Cancer and Prostatic Diseases |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - 2002 |
Externally published | Yes |
Keywords
- Adrenoceptor antagonist
- Apoptosis
- Prostate
- Quinazoline
- TGF-β